Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash & Equivalents (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cash & Equivalents for 9 consecutive years, with $184.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 256.36% to $184.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $184.8 million, a 256.36% increase, with the full-year FY2025 number at $184.8 million, up 256.36% from a year prior.
  • Cash & Equivalents was $184.8 million for Q4 2025 at Akebia Therapeutics, up from $166.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $247.0 million in Q2 2021 to a low of $34.0 million in Q3 2024.
  • A 5-year average of $106.7 million and a median of $101.9 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 67.86% in 2023, then skyrocketed 389.14% in 2025.
  • Akebia Therapeutics' Cash & Equivalents stood at $149.8 million in 2021, then tumbled by 39.61% to $90.5 million in 2022, then plummeted by 52.55% to $42.9 million in 2023, then increased by 20.84% to $51.9 million in 2024, then surged by 256.36% to $184.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Cash & Equivalents are $184.8 million (Q4 2025), $166.4 million (Q3 2025), and $137.3 million (Q2 2025).